Key result
Apixaban was superior to warfarin in preventing stroke or systemic embolism and caused less bleeding and lower mortality in patients with atrial fibrillation.
Why the study?
Does apixaban prevent stroke or systemic embolism in patients with atrial fibrillation?
Does apixaban prevent stroke or systemic embolism in patients with atrial fibrillation?
In patients with atrial fibrillation, apixaban is superior to warfarin for preventing stroke or systemic embolism, with the added benefits of less bleeding and lower mortality.
Answers are grounded in this paper and cite their sources.
Apixaban preferred over warfarin in atrial fibrillation; reinforces consensus for NOAC first-line use with lower bleeding and mortality.
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).
No takes yet. Share an insight, caveat, or question.
Granger et al. (2011) studied this question. Apixaban was superior to warfarin in preventing stroke or systemic embolism and caused less bleeding and lower mortality in patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: